menu
    • menu
    [{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Linc AB","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Linc AB"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"BerGenBio ASA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Oncoinvent","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Oncoinvent"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncoinvent

    Menu

    Oncoinvent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : BerGenBio ASA

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            BerGenBio and Oncoinvent Announce Proposed Merger and a Fully Underwritten Rights Issue

                            Details : The proposed merger between BerGenBio and Oncoinvent centers around Oncoinvent's lead product candidate, Radspherin, which is in active clinical development as a novel radiopharmaceutical therapy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : BerGenBio ASA

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Linc AB

                            Deal Size : $11.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Oncoinvent ASA Announces Oversubscribed Private Placement

                            Details : The net proceeds from the financing will be used for the advancement of Radspherin (Alpha-emitting Radionuclide) for the treatment of peritoneal metastases originating from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 05, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Linc AB

                            Deal Size : $11.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Reports Promising Interim Radspherin® Data for Peritoneal Carcinomatoses

                            Details : Radspherin is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. It is under development for peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Doses First Patient in Radspherin® Phase 2 Trial For Ovarian Cancer

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere, which is under clinical development for treatment of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Radspherin® in Patients with Primary Advanced Epithelial Cancer, with Peritoneal Metastasis That...

                            Details : Radspherin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peritoneal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Receives FDA Fast Track for Radspherin® in Ovarian Cancer Treatment

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere, which is under clinical development for treatment of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovar...

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. It is under phase 1/2 clinical development for treatmemt of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colo...

                            Details : Radspherin (alpha-emitting radioactive micro particle suspension) is a novel treatment principle especially designed to give local radiation to the surface of the abdominal cavity. It is being evaluated for patients with peritoneal carcinomatosis from co...

                            Product Name : Radspherin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Initiates Radspherin® Phase 2A Trial

                            Details : RAD-18-002 (Radspherin) ®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities, has in animal models been shown to cause reduction in tumour cell growth and a significant increased survival.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 25, 2022

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Data From the Ongoing Radspherin® RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at t...

                            Details : The biodistribution of Radspherin, consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension, showed relatively even peritoneal distribution, and no patients had compartments of the abdominal cavity wit...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Radspherin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth